For plasma cell isolation ex vivo from bone marrow, mice were immunised with ovalbumin, followed by a second immunisation after 3 weeks.
DBA/1 mice were immunised with CII in CFA; 13 days after immunisation, the mice were treated every second day with 0.25 mg of anti-CD25 (PC61) or control IgG antibodies, for 4 weeks (injected intraperitoneally).
HHD mice were immunised with individual peptides, splenocytes were re-stimulated in vitro with the immunising peptide, and cytotoxicity against cells loaded with the immunising peptide was measured.
BALB/c mice were immunised with GnRH lipopeptide conjugates, co-administered with or without Complete Freund's Adjuvant, followed by two additional immunisations.
Female C57BL/6 mice were immunised using the rVV-Ag85 constructs, and interleukin-2 and gamma-interferon were assayed using a co-culture of immune splenocytes and recall antigen.
OT-II mice were immunised for the indicated periods of time and fed with 5-Bromo-2'-deoxyuridine (BrdU; 800 µg/ml) in drinking water for three days.
IFNAR −/− mice were immunised by two intraperitoneal injections of MVA-VP2 administered on days 0 and 28 using 107 pfu/mouse.
SJL/J mice were immunised by injection of 200 µg of murine PLP (aa139 151, Pepceuticals Limited, UK), emulsified in Complete Freund's adjuvant (CFA) (Difco Laboratories, Detroit, Michigan, USA) supplemented with 500 µg Mycobacterium tuberculosis (Difco Laboratories).
Balb/c mice were immunised with mis-disordered tau protein 151-391/4R.
